Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases
involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory
microenvironment.